Werewolf Therapeutics, Inc. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Werewolf Therapeutics agreed to merge with Ambros Therapeutics (via merger sub Wave Atlantis) in an all-stock transaction. Ambros equity valued at $500M, Werewolf at $47.5M; combined company to be named Ambros Therapeutics. Concurrent PIPE financing of $150M gross proceeds. Werewolf shareholders receive CVRs tied to legacy asset monetization. Deal dated August 21, 2026; stockholder votes and regulatory approvals required to close.
Why this rating
Transformational for $39.6M Werewolf: acquiring $500M partner (12.6× larger), adding $150M PIPE capital, becoming $697.5M+ enterprise. Business fundamentally changes ownership, strategy, and scale—meets acquisition threshold.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.